CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
2022-04-06 · CNS Pharmaceuticals, Inc. · original cnspharma.com ↗
Company continues to drive global patient enrollment in pivotal study of Berubicin HOUSTON, April 6, 2022 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from the National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority and from the People Protection Ethics Committee (EC) SUD-EST III (CPP Sud-Est III) in France for the Company’s potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
The release as fetched from its publisher. cnspharma.com ↗